Health Care
Nordic 260 response rate: Health Care Overall: 36% (9 of 25)
Key Industries within the sector: Pharmaceuticals (4 of 8); Health Care Equipment & Supplies (4 of 8); Biotechnology (1 of 7)
Responders Coloplast Elekta
Genmab Getinge Lundbeck Meda
Novo Nordisk Orion William Demant Holding
Largest non-respondents include: GN Store Nord, Active Biotech, Swedish Orphan Biovitrum
Opportunities reported • Preference in public procurement for companies with strong performance on carbon management.
• Increased need for certain treatments (e.g. respiratory diseases, skin cancers) owing to the physical effects of climate change.
• Attraction of employees, investors and customers through establishing a reputation for leadership on climate change.
Risks reported • Increased operational costs if chemical production plants are subject to carbon taxation and/or emissions trading.
• Increased costs of transport and certain raw materials owing to carbon taxes and regulation.
• Vulnerability of distribution networks to extreme weather events
Fig 26: Emissions disclosure (million metric tons CO2e)
(67% disclosed) Scope 3
(67% disclosed) Scope 2
(89% disclosed)
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 Scope 1
Key actions • Measures to improve energy efficiency in laboratories and production plants, e.g. waste heat recovery, automatic shutdown of pumps, etc.
• Campaigns and incentives for employees to commute using carpools and public transport, and to turn off computers, lights, etc.
• Greater use of renewable energy, including geothermal heating, groundwater cooling and wood-fired boilers.
‘We are seeing more and more public and private tenders having environmental and climate requirements, and we have won quite a few tenders based on our ‘green’ performance.’
Coloplast
Performance indicators Average disclosure score Verification rate Scope 1 Verification rate Scope 2
Share with emissions reduction targets Change in emissions during 2010
Nordic 260 64
47% 38% 67%
+0.9%
Health Care 64
33% 33% 44%
-0.4%
45
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62